PNU-288034

Class: Oxazolidinone

Spectrum of activity:	Gram-negative
Details of activity:	Use against Endocarditis infections
Institute where first reported:	Pharmacia Corporation (Pfizer)
Year first mentioned:	2002
Highest developmental phase:	Phase 1
Development status:	Inactive
Reason Dropped:	This was probably one of a long series of oxazolidinones from Pharmacia - not followed up on by Pfizer. Likely no signficant improvement over linezolid. Lots of companies worked on oxazolidinones after Pharmacia/Pfizer registered linezolid. There are some toxicities that it has been hard to overcome. A newer oxazolidinone [tadezolid] may have some potency improvements over linezolid [and activity against some linezolid resistant bugs, which are not prevalent]- (LS)

Chemical structure(s):
Canonical SMILES:	CC(=O)NC[C@H]1CN(C2=CC(=C(C(=C2)F)N3CCS(=O)(=O)CC3)F)C(=O)O1
Isomeric SMILES:	CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C(=C2)F)N3CCS(=O)(=O)CC3)F
InChI:	InChI=1S/C16H19F2N3O5S/c1-10(22)19-8-12-9-21(16(23)26-12)11-6-13(17)15(14(18)7-11)20-2-4-27(24,25)5-3-20/h6-7,12H,2-5,8-9H2,1H3,(H,19,22)/t12-/m0/s1
InChI Key:	HSGZLFWXBIVLBD-LBPRGKRZSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/9931003

External links:
Guide to Pharmacology:	PNU-288034
Citation:	http://jpet.aspetjournals.org/content/334/3/936.long